David M. Knott’s Xenon Pharmaceuticals XENE Stock Holding History

David M. Knott’s Portfolio XENE Stock Details XENE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	$1.44M	Sell	94,488 -46,063	-33%	-$800K	0.52%	47
2021 Q2	$2.62M	Sell	140,551 -3,550	-2%	-$65.4K	0.93%	31
2021 Q1	$2.58M	Sell	144,101 -55,899	-28%	-$947K	1.1%	23
2020 Q4	$3.08M	Buy	200,000 +23,000	+13%	+$269K	1.39%	21
2020 Q3	$1.96M	Buy	177,000 +8,000	+5%	+$94.1K	1.15%	22
2020 Q2	$2.12M	Sell	169,000 -6,204	-4%	-$79K	1.16%	23
2020 Q1	$1.99M	Sell	175,204 -20,453	-10%	-$291K	1.25%	19
2019 Q4	$2.56M	Buy	195,657 +8,346	+4%	+$87.8K	1.04%	23
2019 Q3	$1.69M	Buy	187,311 +7,921	+4%	+$74.9K	0.71%	28
2019 Q2	$1.77M	Hold	179,390	–	–	0.75%	25
2019 Q1	$1.82M	Buy	179,390 +6,000	+3%	+$50.9K	0.73%	31
2018 Q4	$1.09M	Hold	173,390	–	–	0.51%	37
2018 Q3	$2.29M	Hold	173,390	–	–	0.74%	27
2018 Q2	$1.59M	Buy	173,390 +58,490	+51%	+$363K	0.6%	31
2018 Q1	$563K	Buy	114,900 +20,900	+22%	+$77.3K	0.23%	57
2017 Q4	$266K	Buy	94,000 +49,000	+109%	+$133K	0.11%	77
2017 Q3	$133K	Buy	+45,000	New	+$139K	0.06%	81

Other funds holding XENE

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

David M. Knott's XENE Position: Q3 2021 in Review

David M. Knott reduced its Xenon Pharmaceuticals (XENE) stake by 33% in Q3 2021, selling an estimated $800K and leaving 94,488 shares worth $1.44M. The position accounts for 0.52% of the portfolio, ranked #47.

David M. Knott first reported a position in XENE in Q3 2017 and has held it in 17 quarters since. The position peaked at $3.08M in Q4 2020. 118 funds tracked by Wall St. Rank hold XENE as of Q3 2021.

David M. Knott held 94,488 shares of Xenon Pharmaceuticals worth $1.44M as of Q3 2021.
David M. Knott sold 46,063 Xenon Pharmaceuticals shares in Q3 2021, an estimated $800K.
Xenon Pharmaceuticals made up 0.52% of David M. Knott's portfolio in Q3 2021, its #47 holding.
David M. Knott first reported a position in Xenon Pharmaceuticals in Q3 2017 and has held it in 17 quarters since.
David M. Knott's Xenon Pharmaceuticals position peaked at $3.08M in Q4 2020.
118 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q3 2021.

Based on David M. Knott's 13F filing for Q3 2021, filed 12 Nov 2021.